-- 德国蓝筹股DAX指数周三收盘上涨2.24%,加入全球股市上涨行列,这主要得益于市场对伊朗战争可能结束的乐观情绪重燃。 美国总统特朗普在宣布暂停护送船只离开霍尔木兹海峡的行动时,提到在达成最终解决方案方面取得了“巨大进展”,并表示“以观察能否最终敲定并签署协议”。路透社援引一位不愿透露姓名的巴基斯坦调解员的话报道称,美巴两国即将敲定一份旨在停止该地区敌对行动的单页备忘录。 在国内,最终商业调查数据显示,德国私营部门近一年来首次出现萎缩。标普全球数据显示,德国4月份综合采购经理人指数(PMI)终值从上月的51.9降至48.4,高于48.3的初值。服务业方面,最终PMI为46.9,与初值一致,高于上月的50.9。 “继4月份服务业业务活动大幅下滑之后,德国经济在第二季度出现萎缩的可能性有所上升。与制造业在一定程度上受到库存增加支撑不同,服务业直接受到中东战争对需求的冲击,经历了近三年半以来最严重的下滑,”标普全球市场情报经济副总监菲尔·史密斯表示。 企业新闻方面,宝马集团(BMW.F)表现突出,收盘上涨5.41%。尽管第一季度营收下滑,但加拿大皇家银行资本市场指出,宝马汽车业务息税前利润(EBIT)好于预期,并重申了2026年全年业绩指引,尽管面临美国最新的关税威胁。这家德国汽车制造商的营收下降8.1%至310.1亿欧元。 尽管近期有消息称欧盟对美国汽车进口关税将恢复至25%,宝马仍重申了其2026年的业绩指引,并预计关税将对其全年业绩产生125个基点的影响。宝马表示有信心达成协议,并特别预计欧盟对美国进口汽车的关税将在2026年下半年降至0%,墨西哥和加拿大的关税下调也将在2026年下半年生效。研究机构指出:“我们的计算表明,2026年剩余时间内,宝马汽车行业的息税前利润(EBIT)预期可能会进一步提高。” 大陆集团(CON.F)也是当日表现最佳的股票之一,收盘上涨8.95%。这家德国汽车零部件制造商公布第一季度销售额为 44 亿欧元,同比下降 10.4%,但略高于 43.9 亿欧元的普遍预期。尽管地缘政治存在不确定性,该公司仍维持全年营收预期在 173 亿欧元至 189 亿欧元之间。
Related Articles
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%